目的 探讨复方血栓通胶囊联合依帕司他片治疗糖尿病肾病的临床疗效。方法 选取2018年10月—2020年12月佛山市高明区中医院收治98例糖尿病肾病患者作为研究对象，按照随机数字表法将98例患者分为对照组和治疗组，每组各49例。对照组口服依帕司他片，50 mg/次，3次/d。治疗组在对照组基础上口服复方血栓通胶囊，1.5 g/次，3次/d。两组患者连续治疗3个月。观察两组临床疗效，比较两组治疗前后的生活质量、血糖指标和肾功能指标。结果 治疗后，治疗组的总有效率为93.88%，对照组总有效率为83.67%，组间比较差异有统计学意义（P<0.05）。治疗后，两组的糖尿病生存质量特异性量表（QSQL）评分显著降低（P<0.05），以治疗组QSQL评分降低的更明显（P<0.05）。治疗后，两组的空腹血糖（FBG）、餐后2小时血糖值（2 h PG）、糖化血红蛋白（HbA1c）明显降低（P<0.05）；治疗后两组的FBG、2 h PG、HbA1c对比，差异无统计学意义。治疗后，两组的胱抑素C（Cys-C）、转化生长因子-β₁（TGF-β₁）、尿白蛋白排泄率（UAER）水平显著降低（P<0.05）；治疗后，治疗组患者的Cys-C、TGF-β₁、UAER水平比对照组低，差异有统计学意义（P<0.05）。结论 复方血栓通胶囊联合依帕司他片治疗糖尿病肾病的疗效确切，可改善生活质量和肾功能，且安全性良好。

Objective To investigate the clinical efficacy of Compound Xueshuantong Capsules combined with Epalrestat Tablets in treatment of diabetic nephropathy. Methods Patients (98 cases) with diabetic nephropathy in Foshan Gaoming District Hospital of Traditional Chinese Medicine from October 2018 to December 2020 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Epalrestat Tablets, 50 mg/time, three times daily. Patients in the treatment group were po administered with Compound Xueshuantong Capsules on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and quality of life, blood glucose, and renal function in two groups were compared before and after treatment. Results After treatment, the total effective rate of the treatment group was 93.88%, and that of the control group was 83.67% (P<0.05). After treatment, the QSQL scores of two groups were significantly decreased (P<0.05), and the QSQL scores of the treatment group were significantly lower than those of the control group (P<0.05). After treatment, the FBG, 2 h PG, and HbA1c of two groups were significantly decreased (P<0.05). After treatment, there was no significant difference in FBG, 2 h PG, and HbA1c between two groups. After treatment, the levels of Cys-C, TGF-β₁, and UAER in two groups were significantly decreased (P<0.05). After treatment, the levels of Cys-C, TGF-β₁, and UAER in the treatment group were significantly lower than those of the control group (P<0.05). Conclusion Compound Xueshuantong Capsules combined with Epalrestat Tablets are effective in the treatment of diabetic nephropathy, can improve renal function and quality of life, with good safety.

R983

广东省医学科研基金资助项目（B2021340）